Cargando…
Liraglutide effects in a paediatric (7‐11 y) population with obesity: A randomized, double‐blind, placebo‐controlled, short‐term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics
BACKGROUND: Childhood obesity is a major public health concern with limited treatment options. OBJECTIVE: The aim of this study was to assess safety, tolerability, pharmacokinetics, and pharmacodynamics during short‐term treatment with liraglutide in children (7‐11 y) with obesity. METHODS: In this...
Autores principales: | Mastrandrea, Lucy D., Witten, Louise, Carlsson Petri, Kristin C., Hale, Paula M., Hedman, Hanna K., Riesenberg, Robert A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590663/ https://www.ncbi.nlm.nih.gov/pubmed/30653847 http://dx.doi.org/10.1111/ijpo.12495 |
Ejemplares similares
-
Liraglutide pharmacokinetics and exposure‐response in adolescents with obesity
por: Carlsson Petri, Kristin C., et al.
Publicado: (2021) -
Comparable Liraglutide Pharmacokinetics in Pediatric and Adult Populations with Type 2 Diabetes: A Population Pharmacokinetic Analysis
por: Petri, Kristin C. Carlsson, et al.
Publicado: (2015) -
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
por: Jacobsen, Lisbeth V., et al.
Publicado: (2015) -
Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
por: Liu, Hongzhong, et al.
Publicado: (2021) -
Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: A randomized, single-blind, placebo-controlled study
por: Chen, Qian, et al.
Publicado: (2018)